Rapid bladder cancer test NMP22®

proteinurinestrip

The Alere NMP22® BladderChek® Test is a fast, easy to use and non-invasive test that aids in the diagnosis and monitoring of bladder cancer, in conjunction with standard diagnostic procedures. With results in 30 minutes at the point-of-care, results can be delivered to patients during the same office visit, allowing a rapid and cost-effective aid in the detection of bladder cancer in patients at risk. BENEFITS CE-marked and CLIA-waived. FDA cleared in the US for professional point-of-care and prescription home use. Ability to test patients at risk for bladder cancer. Easy testing process, only requiring 4 drops of urine to run the test. Fast results in 30 minutes, allowing consultation during the same visit. An ideal adjunct marker to cystoscopy as found in one study: 99% sensitivity when combined with cystoscopy, giving greater confidence that recurrent cancer has been detected.1 99% NPV overall when combined with cystoscopy, the most effective diagnostic combination for ruling out bladder cancer.1,2